<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10360656</article-id><article-id pub-id-type="pmc">2362283</article-id><article-id pub-id-type="pii">6690422</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690422</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>A randomized phase II trial of 5-fluorouracil, with or without human interferon-&#x003b2;, for advanced colorectal cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Villar-Grimalt</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Candel</surname><given-names>M T</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Massuti</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Liz&#x000f3;n</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>S&#x000e1;nchez</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Frau</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Gorostidi</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Goedkoop</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><aff id="aff1">H. Arnau de Vilanova, Valencia, Spain</aff><aff id="aff2">H. General de Alicante, Alicante, Spain</aff><aff id="aff3">H. San Juan, Alicante, Spain</aff><aff id="aff4">H. Provincial, Castell&#x000f3;n, Spain</aff><aff id="aff5">Laboratorios Serono S.A., Madrid, Spain</aff><aff id="aff6">Ares-Serono S.A., 15 bis chemin des Mines, Geneva, 1202, Switzerland</aff></contrib-group><pub-date pub-type="ppub"><month>5</month><year>1999</year></pub-date><volume>80</volume><issue>5-6</issue><fpage>786</fpage><lpage>791</lpage><history><date date-type="received"><day>20</day><month>05</month><year>1998</year></date><date date-type="rev-recd"><day>29</day><month>10</month><year>1998</year></date><date date-type="accepted"><day>19</day><month>11</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>This study compared the efficacy and safety of 5-fluorouracil (5-FU) monotherapy to that of 5-FU combined with natural human interferon-&#x003b2; (IFN-&#x003b2;) in patients with unresectable, advanced colorectal carcinoma. Forty-nine chemotherapy-naive patients were randomized to 5-FU alone or to the combination. All patients received 750 mg m<sup>&#x02212;2</sup> day<sup>&#x02212;1</sup> 5-FU for 5 days by continuous intravenous (i.v.) infusion, followed after day 15 by a weekly i.v. bolus of 750 mg m<sup>&#x02212;2</sup>. IFN-&#x003b2; was injected intramuscularly three times weekly at 9 <sc>M</sc> IU. Treatment continued for 52 weeks, or until disease progression or intolerable toxicity. Clinical endpoints were tumor response, time to progression, survival and toxicity. The addition of IFN-&#x003b2; to 5-FU significantly improved response rate (33.3&#x00025; vs 4.5&#x00025; for evaluable patients; <italic>P</italic> = 0.021), time to progression (median 7.2 vs 4.2 months; <italic>P</italic> = 0.0435), and survival time (median 15.9 vs 7.2 months; <italic>P</italic> = 0.038) without significantly increasing toxicity compared to 5-FU alone. Cumulative 5-FU dose was higher with combined therapy (<italic>P</italic> &#x0003c; 0.001): more patients receiving monotherapy discontinued treatment because of disease progression. Fever was more frequent with combined therapy (<italic>P</italic> = 0.008); there were no other differences in toxicity. The only grade IV toxicity observed was neutropenia (two patients per group). A randomized phase III trial has been initiated to confirm the synergy between 5-FU and IFN-&#x003b2;. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>colorectal cancer</kwd><kwd>5-fluorouracil</kwd><kwd>interferon-&#x003b2;</kwd><kwd>synergism</kwd><kwd>survival</kwd></kwd-group></article-meta></front></article>
